ArticleCureus2026
Cardiometabolic Response to Saroglitazar in a Young Indian Man With Obesity, Prediabetes, Insulin Resistance, and High-Normal Albuminuria: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 22-year-old Indian man presented to the outpatient clinic for a routine health check and had a body mass index (BMI) of 27.6 kg/m², which falls within the obesity range according to the Consensus Statement for Asian Indians, although it would be classified as overweight by Western cut-offs. Laboratory evaluation revealed prediabetes according to American Diabetes Association (ADA) criteria, along with elevated liver enzymes, insulin resistance, and high-normal urine albumin-to-creatinine ratio (UACR). Saroglitazar 4 mg once daily was initiated with structured lifestyle counselling. After three months of treatment, the patient demonstrated improvements in glycemic control, insulin resistance, liver enzyme levels, and urinary albumin excretion. A concurrent weight reduction of 1.3 kg was observed following initiation of saroglitazar, despite no reported changes in lifestyle modification or dietary advice compared with the two preceding visits, during which no weight change had occurred; however, this modest change may fall within ordinary biological variation, and its relative contribution from lifestyle versus pharmacological factors cannot be established from this single, uncontrolled observation. The overall direction of these changes suggests potential beneficial effects of early pharmacological intervention across metabolic, hepatic, and renal parameters. However, adequately powered controlled trials are needed before such early intervention strategies can be recommended for routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.